Raymond James Financial
IBRX icon

Raymond James Financial’s ImmunityBio IBRX Stock Holding History

Raymond James Financial’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.88M Buy
375,701
+164,466
+78% +$1.13M ﹤0.01% 3058
2025
Q4 		$418K Sell
211,235
-28,262
-12% -$64K ﹤0.01% 4381
2025
Q3 		$589K Buy
239,497
+86,437
+56% +$223K ﹤0.01% 4015
2025
Q2 		$404K Buy
153,060
+68,956
+82% +$185K ﹤0.01% 4129
2025
Q1 		$253K Buy
84,104
+16,750
+25% +$50.8K ﹤0.01% 4301
2024
Q4 		$172K Buy
+67,354
New +$281K ﹤0.01% 4435

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Raymond James Financial's IBRX Position: Q1 2026 in Review

Raymond James Financial increased its ImmunityBio (IBRX) stake by 78% in Q1 2026, buying an estimated $1.13M and bringing the position to 375,701 shares worth $2.88M. The position accounts for ﹤0.01% of the portfolio, ranked #3058.

Raymond James Financial first reported a position in IBRX in Q4 2024 and has held it in 6 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Raymond James Financial held 375,701 shares of ImmunityBio worth $2.88M as of Q1 2026.
  • Raymond James Financial bought 164,466 ImmunityBio shares in Q1 2026, an estimated $1.13M.
  • ImmunityBio made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3058 holding.
  • Raymond James Financial first reported a position in ImmunityBio in Q4 2024 and has held it in 6 quarters since.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.